FR255734 monoclonal antibody
In vitro studies have shown that FR255734 effectively blocked T-cell proliferation and proinflammatory cytokine production. These observations warrant studies to evaluate the efficacy of FR255734 in human autoimmune diseases.
relevant articles (1 outcomes,
Bio-Agent Context: Research Results
|1. ||Autoimmune Diseases (Autoimmune Disease)
|2. ||Psoriasis (Pustulosis Palmaris et Plantaris)
- "Here, using the severe combined immunodeficient (SCID) mouse-psoriasis xenograft model, we report therapeutic efficacy of a humanized anti-CD28 monoclonal antibody (FR255734; Astellas Pharmaceuticals Inc., Tokyo, Japan).
- "FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model.
- "Transplanted psoriasis plaques on the SCID mouse were treated weekly for 4 weeks with intraperitoneal injections of FR255734 at 10, 3, and 1-mg kg(-1) doses.
Related Drugs and Biologics
Related Therapies and Procedures